

Special Issue

Inhibitors in Thyroid Carcinoma

Message from the Guest Editor

The aim of this Special Issue will be to review and discuss new advancements in the therapy of aggressive iodine refractory thyroid carcinoma (RAI-TC). The most common altered signaling found in aggressive RAI-TC are RTK, MAPK, PI3K, WNT, BRAF, RAS, RET, and TP53. Sorafenib and lenvatinib are tyrosine kinase inhibitors (TKI) that have recently been approved for the treatment of RAI-TC. These drugs are able to elicit an anti-neoplastic activity by acting against different pathways. Other studies are evaluating vandetanib and selumetinib in RAI-TC, as well as dabrafenib, and vemurafenib in BRAF mutated RAI-TC patients to re-induce ¹³¹-iodine uptake. Different mechanisms of resistance to TKIs inhibitors can occur. Therefore, anti-FGFR agents are evaluated. Additionally, knowing the genetic signature of the cancer is very important in order to choose the right treatment avoiding the administration of inefficacious drugs, and also to explore new ways to fight the tumor. A new investigating field is about the interplay between cells of the immune system and cancer cells. The expression of PDL1 in RAI-TC has been related to tumor recurrence and poor survival.

Guest Editor

Prof. Dr. Alessandro Antonelli

Department of Clinical and Experimental Medicine, University of Pisa,
56100 Pisa, Italy

Deadline for manuscript submissions

closed (5 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/125619

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)